Funding for this research was provided by:
National Institute of Child Health and Human Development (R01 HD83113)
National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK104676)
Received: 8 February 2017
Accepted: 23 August 2017
First Online: 4 September 2017
: CRS and MW are Assistant Professors, WWF and CPD are Professors, and DS is a ScD student at the Harvard T.H. Chan School of Public Health. KPM is a Professor, SA an Associate Professor, and FMAA is a Lecturer at Muhimbili University of Health and Allied Sciences, and KPM, SA, DS, and FMAA are also affiliated with Management and Development for Health.
: The ToV5 protocol was approved by the Harvard T.H. Chan School of Public Health Institutional Review Board (reference no. IRB14-3416), the Tanzanian National Health Research Ethics Sub-Committee (NatHREC; reference no. NIMR/HQ/R.8a/Vol.IX/1933), and the Tanzania Food and Drug Authority (TFDA; reference no. TFDA15/CTR/0003/5). All participants will provide written informed consent for both screening and trial enrollment. Individuals who consent for trial enrollment are also asked for consent to escort the participant home to register the address, to contact the participant, neighbors, or relatives by cell phone or a home visit if the participant misses a clinic visit, and to store and use of all data and maternal and child blood samples for future research studies.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.